Portal flow diversion based on portography is superior than puncture site in the prediction of overt hepatic encephalopathy after TIPS creation

Chongtu Yang1,2†, Yang Chen1,2†, Chaoyang Wang1,2†, Jiacheng Liu1,2, Songjiang Huang1,2, Chen Zhou1,2, Yingliang Wang1,2, Shuguang Ju1,2, Tongqiang Li1,2, Yaowei Bai1,2, Wei Yao1,2 and Bin Xiong1,2*

Abstract
Background: Targeted puncture of an appropriate portal venous branch during transjugular intrahepatic portosystemic shunt (TIPS) procedure may reduce the risk of postprocedural overt hepatic encephalopathy (HE). This study aimed to describe blood distribution under portography and combined it with puncture site to determine portal flow diversion, and to evaluate its prognostic value in predicting post-TIPS overt HE.

Methods: In this retrospective analysis of patients with cirrhosis undergoing TIPS, we included 252 patients to describe blood distribution under portography and 243 patients to assess the association between portal flow diversion and post-TIPS overt HE.

Results: At the first stage, 51 (20.2%) patients were identified as type A (unilateral type with the right portal branch receives blood from splenic vein [SV]), 16 (6.4%) as type B (unilateral type with the right branch receives blood from superior mesenteric vein [SMV]) and 185 (73.4%) as type C (fully mixed type). At the second stage, 40 patients were divided into the SV group, 25 into the SMV group and 178 into the mixed group. Compared with the mixed group, the risk of post-TIPS overt HE was significantly higher in the SMV group (adjusted HR 3.70 [95% CI 2.01–6.80]; \( p < 0.001 \)), whereas the SV group showed a non-significantly decreased risk (adjusted HR 0.57 [95% CI 0.22–1.48]; \( p = 0.25 \)). Additionally, the SMV group showed a substantial increase in ammonia level at 3 days and 1 month after procedure.

Conclusions: Our results support the clinical use of portal flow diversion for risk stratification and decision-making in the management of post-TIPS overt HE.

Keywords: Cirrhosis, Portal hypertension, Portosystemic shunt, Transjugular intrahepatic, Hepatic encephalopathy, Portography

Introduction
Currently, transjugular intrahepatic portosystemic shunt (TIPS) is recommended as a standard procedure for treating portal hypertension-related complications in patients with cirrhosis [1, 2]. However, the high prevalence of postprocedural overt hepatic encephalopathy (HE) limits the effectiveness and broad use of this

1 Chongtu Yang, Yang Chen and Chaoyang Wang contributed equally to this work

*Correspondence: herr_xiong@126.com

1 Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue #1277, Wuhan 430022, China

Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
procedure, with a reported incidence ranging from 10 to 50% within 1 year [3, 4].

Diversion of undetoxified portal blood into the systemic circulation is one of the major mechanisms involved in the pathogenesis of post-TIPS overt HE, which degree is related to the diameter and position of the stent. The association between stent diameter and overt HE has been well established [5, 6], while the effect of stent position on the outcome has not been fully elucidated. An early randomized-controlled trial (RCT) and few observational studies suggested that puncture of the left branch of portal vein (PV) might decrease the risk of post-TIPS overt HE compared to the right branch [7–13], and the potential mechanism might be related to the unbalanced distribution of blood flow from splenic vein (SV) and superior mesenteric vein (SMV) in the intrahepatic portal system. However, this theory lacks of hemodynamic evidence and may not be applicable to all cirrhotic patients due to anatomic variation.

During TIPS procedure, portography is performed to evaluate the portal system after access from the hepatic vein to the PV, which clearly demonstrates distribution of blood flow from the SMV and SV to the PV and its tributaries, and from a hemodynamic point of view, this approach is more accurate than assuming all patients have the same pattern of intrahepatic blood distribution. Thus, the first aim was to describe the distribution of intrahepatic portal blood from SMV and SV under intraprocedural portography, and the second aim was to combine portal blood distribution with puncture site to determine the type of portal flow diversion and evaluate its prognostic value in the prediction of post-TIPS overt HE in cirrhotic patients undergoing TIPS placement.

Materials and methods
Study population
From January 2016 to March 2021, all consecutive patients with portal hypertension admitted to receive TIPS creation were retrospectively analyzed. Baseline data regarding demographic characteristics, laboratory results and radiological findings were collected for each patient during hospitalization. Details of treatment were retrieved from electronic medical records. Follow-up at outpatient was scheduled for all patients at 1, 3, 6 and 12 months and then annually after procedure, supplemented with telephone interviews every 3 months. Patients were followed until death, liver transplantation or the end of the study (September 2021), and data were censored at the end of follow-up. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institutional ethics committee.

Blood distribution and portal flow diversion
Details of TIPS procedure has been described previously [14]. In brief, access from the hepatic vein to PV were routinely established by blind fluoroscopic puncture. Afterwards, a hydrophilic wire and catheter were advanced to the SV or SMV (mostly the former) to perform the first portography to visualize the portal system. After dilating the tract with an angioplasty balloon and deploying a PTFE-covered stent, another portography was performed to confirm the stent position. Portography was obtained during a breath hold at the end of inspiration.

Blood distribution and flow diversion were determined by analyzing opacification of the portal venous branches using the first portography (before stent insertion). The first stage was to determine blood distribution from SV and SMV. Portography of the eligible patients were divided into two types: the unilateral type and bilateral type. The unilateral type indicates blood from SV and SMV were not fully mixed in the intrahepatic portal system (unilateral opacification of the PV under portography), and this type was further subdivided into the type A (the right branch receives blood from SMV and the left branch receives blood from SMV) and type B (the right branch receives blood from SMV and the left branch receives blood from SV). The bilateral type (type C) indicates blood flow from SV and SMV were fully mixed (both left and right portal branch were opaque). The second stage was to determine portal flow diversion by taking puncture site into account. After excluding patients with puncturing the main portal venous bifurcation, the unilateral type were divided into the SV superiority type (SV group) and SMV superiority type (SMV group), with the former diverting blood from SV (puncture of the right branch for type A and the left branch for type B) and the latter diverting blood from SMV (puncture of the left branch for type A and the right branch for type B). Patients with bilateral type were classified as the mixed.
type (mixed group) regardless of puncturing the left or right branch (Fig. 1).

Blood distribution was determined by two researchers who were specialized in TIPS procedure. Both researchers independently assessed the DSA records of all patients, and resolved disagreements by discussion and making consensus. Inter-reviewer agreement was evaluated by kappa value calculation, which showed an excellent consistency in this study (kappa 0.879 [95% CI 0.811–0.945]).

**Endpoint definition**

The primary endpoint of the study was incidence of post-TIPS overt HE. The spectrum of cognitive impairment occurred in a continuum and was subdivided into five grades according to the West Haven Criteria, only a grade II or higher was considered an episode of overt HE [4]. Due to the subjectivity of the diagnosis of overt HE, researchers responsible for the follow-up procedure were blinded to patients' baseline characteristics. Secondary endpoints included changes of ammonia level at 3 days and 1 month after procedure.

**Statistical analysis**

Quantitative variables are presented as means and SDs and categorical variables are presented as frequencies and percentages. Comparison between groups were conducted by Student t-test, Mann-Whiney test, Chi-squared test or Fisher's exact test as appropriate.

Time-dependent endpoints were assessed by Kaplan–Meier curves and compared with log-rank tests. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for

![Fig. 1](image)

**Fig. 1** Blood distribution and portal flow diversion under portography. **A, B, C** Blood distribution. A Represents type A (unilateral type with the right portal branch receives blood from SV), B represents type B (unilateral type with the right branch receives blood from SMV), C represents type C (bilateral opacification). **D, E, F** Portal flow diversion. D Represents SV superiority type (TIPS shunt diverts blood from SV), E represents SMV superiority type (TIPS shunt diverts blood from SMV), F represents mixed type (type C regardless of the puncture site). **G, H, I** Flow diversion under portography during TIPS procedure. G Represents SV superiority type (case with type A and puncture of the right branch), H represents SMV superiority type (case with type A and puncture of the left branch), I represents mixed type (case with mixed type and puncture of the left branch). SV splenic vein, SMV superior mesenteric vein, PV portal vein.
risk of the primary outcome were calculated with Cox proportional hazards models, and odds ratios (ORs) and 95% CIs for risk of secondary outcome were calculated with logistic regression models. Three models were built to adjust for potential confounders; in model A age and Child–Pugh score were adjusted; in model B age, Child–Pugh score and post-TIPS portal pressure gradient (PPG) were adjusted; in model C age, Child–Pugh score, post-TIPS PPG and puncture site (left or right branch) were adjusted. Additionally, two sets of subgroup analyses according to flow diversion and puncture site were conducted.

Sensitivity analysis based on Fine and Gray competing risk models were implemented, in which death and liver transplantation were considered as competing events for post-TIPS overt HE. For covariables included in the multivariable models, missing values were assumed to be missing at random, thereby were imputed using multiple imputations with chained equations. Statistical significance was set as \( p < 0.05 \) (two-sided). All analyses were performed using IBM SPSS (version 25.0) and R (version 4.0.3) with the add-on packages mice, rms, survival and cmpsk.

**Results**

**Patient classification and general characteristics**

Between January 2016 and March 2021, 439 consecutive patients scheduled to TIPS placement were screened retrospectively. At the first stage, 187 patients were excluded and for the remaining 252 patients, portography was analyzed to determine portal blood distribution, including 67 (26.6%) cases with unilateral opacification of the PV and the remaining 185 cases with bilateral opacification (type C). Among the 67 cases, 51 (76.1%) cases were further classified as type A and 16 cases were classified as type B (Fig. 2). Compared with type A and B, patients with the type C were more frequently female, with younger age, and treated TIPS for variceal bleeding.

At the second stage, 9 patients with puncture of portal venous bifurcation were further excluded and 243 patients were included to determine flow diversion. For 51 patients with type A, the right branch was punctured in 32 patients (SV group) and the left branch punctured in 19 patients (SMV group). For 14 patients with type B, the left branch was punctured in 8 patients (SV group) and the right branch punctured in 6 patients (SMV group) (Additional file 1: Fig. S1). Consequently, the final cohort included 40 (16.4%) patients in the SV group, 25 (10.3%) in the SMV group and 178 (73.3%) in the mixed group (Fig. 2). Baseline characteristics did not markedly differ among three groups, except for age \( (p = 0.002) \) and TIPS indication \( (p < 0.001) \). In addition, the SMV group tended to have higher Child–Pugh score (mainly derives from lower albumin level and more severe ascites), higher model for end-stage liver disease score (mainly derives from higher INR level) and lower pre- and post-TIPS PPG (Table 1).

**Primary endpoint**

During a median follow-up of 15.8 (IQR 9.4–26.5) months, 67 patients (27.6%) were identified to develop at least one episode of overt HE, including 8 patients (20.0%) in the SV group, 18 (72.0%) in the SMV group and 44 (24.7%) in the mixed group. Among them, 59 patients experienced a grade III or higher HE and 21 experienced more than one episode (Table 2). The cumulative rate of post-TIPS overt HE was significantly higher in the SMV group compared with the SV group (HR 10.4 [95% CI 3.8–28.1]; \( p < 0.001 \)) and the mixed group (HR 5.3 [95% CI 3.0–9.2]; \( p < 0.001 \)), but the risk did not markedly differ between the SV group and the mixed group (HR with mixed group: 1.9 [95% CI 0.8–4.9]; \( p = 0.152 \)) (Fig. 3A). After adjusting for potential confounders, the presence of SMV superiority type was associated with a 2.7-fold increased risk of the outcome compared with the mixed type (adjusted HR 3.7 [95% CI 2.01–6.80]; \( p < 0.001 \)), while the relative risk of the SV superiority type was 43% lower than the mixed type, though the difference was not statistically significant (adjusted HR 0.57 [95% CI 0.22–1.48]; \( p = 0.249 \)) (model C in Table 3). In addition, sensitivity analysis based on Fine and Gray competing risk model showed consistent results (Additional file 1: Fig. S2).

**Secondary endpoints**

In the entire cohort, results of ammonia level before and at 3 days after TIPS creation were available in 122 (50.2%) patients, and results before and at 1 month were available in 75 (30.9%) patients. In the SV group, 12 (54.5%) and 9 (75.0%) patients experienced an increase in ammonia level at 3 days and 1 month, and the corresponding values were 17 (80.9%) and 12 (92.3%) in the SMV group, and 52 (65.8%) and 36 (72%) in the mixed group (Table 2, Fig. 4A, B). In the SMV group, median ammonia level increased significantly at 3 days (39 \( \mu \text{mol/L [IQR 25–48]} \) to 66 \( \mu \text{mol/L [IQR 53–79]} \); \( p = 0.002 \)) and 1 month (35 \( \mu \text{mol/L [IQR 25–43]} \) to 74 \( \mu \text{mol/L [IQR 65–94]} \); \( p < 0.001 \)). Similar pattern was observe in the mixed group \((p = 0.007 \text{ and } 0.001, \text{respectively})\), but was not observed in the SV group \((p = 0.46 \text{ and } 0.47, \text{respectively})\) (Fig. 4C, D). Compared with mixed type, the SMV superiority type was associated with a 2.2-fold increased risk of ammonia elevation at 3 days (adjusted HR 3.21 [95% CI 1.07–13.14]; \( p = 0.042 \)), and a 2.8-fold increased risk at 1 month (adjusted HR 3.82 [95% CI 0.59–76.94];
**Fig. 2** Flowchart of the patient selection protocol. TIPS transjugular intrahepatic portosystemic shunt, HCC hepatocellular carcinoma, CTPV cavernous transformation of portal vein, SV splenic vein, SMV superior mesenteric vein
Table 1  Baseline characteristics of the study population

|                          | Total N = 243 | SV group N = 40 | SMV group N = 25 | Mixed group N = 178 | P value |
|--------------------------|---------------|-----------------|------------------|---------------------|---------|
| **Demographics and clinical characteristics** |               |                 |                  |                     |         |
| Age*                     | 54.6 (12.0)   | 54.2 (11.0)     | 62.5 (11.6)      | 53.6 (11.9)         | 0.002   |
| Sex (Male)               | 155 (63.8)    | 26 (65.0)       | 20 (80.0)        | 109 (61.2)          | 0.185   |
| Etiology                 |               |                 |                  |                     | 0.277   |
| Virus related            | 168 (69.1)    | 28 (70.0)       | 14 (56.0)        | 126 (70.8)          |         |
| Alcohol related          | 22 (9.05)     | 5 (12.5)        | 2 (8.00)         | 15 (8.43)           |         |
| AIH                      | 25 (10.3)     | 3 (7.50)        | 2 (8.00)         | 20 (11.2)           |         |
| Others                   | 28 (11.5)     | 4 (10.0)        | 7 (28.0)         | 17 (9.55)           |         |
| **TIPS indication**      |               |                 |                  |                     | <0.001  |
| Variceal bleeding        | 212 (87.2)    | 31 (77.5)       | 17 (68.0)        | 164 (92.1)          |         |
| Refractory ascites       | 31 (12.8)     | 9 (22.5)        | 8 (32.0)         | 14 (7.87)           |         |
| Child–Pugh score*        | 7.53 (1.61)   | 7.15 (1.53)     | 7.96 (1.10)      | 7.55 (1.67)         | 0.131   |
| Child–Pugh class A       | 62 (26.2)     | 13 (32.5)       | 3 (12.0)         | 46 (26.7)           |         |
| B                        | 153 (64.6)    | 25 (62.5)       | 22 (88.0)        | 106 (61.6)          |         |
| C                        | 22 (9.28)     | 2 (5.00)        | 0 (0.00)         | 20 (11.6)           |         |
| MELD score*              | 11.9 (3.68)   | 11.4 (3.10)     | 13.0 (3.45)      | 11.9 (3.82)         | 0.238   |
| MELD-Na score*           | 12.8 (4.71)   | 12.3 (4.40)     | 14.2 (4.77)      | 12.7 (4.76)         | 0.263   |
| **Radiological findings**|               |                 |                  |                     |         |
| Ascites                  |               |                 |                  |                     | 0.005   |
| Mild                     | 84 (34.9)     | 10 (25.6)       | 3 (12.0)         | 71 (40.1)           |         |
| Moderate                 | 39 (16.2)     | 9 (23.1)        | 5 (20.0)         | 25 (14.1)           |         |
| Severe                   | 66 (27.4)     | 6 (15.4)        | 13 (52.0)        | 47 (26.6)           |         |
| Spontaneous porto-systemic shunt (Yes) | 94 (38.7) | 13 (32.5) | 11 (44.0) | 70 (39.3) | 0.828 |
| PV diameter (mm)*        | 15.4 (3.28)   | 14.5 (2.69)     | 15.3 (3.99)      | 15.6 (3.28)         | 0.172   |
| **Laboratory parameters**|               |                 |                  |                     |         |
| Bilirubin (µmol/L)       | 27.9 (28.3)   | 22.8 (11.4)     | 27.0 (13.1)      | 29.3 (32.3)         | 0.419   |
| Albumin (g/L)            | 31.3 (5.53)   | 31.9 (5.37)     | 29.3 (5.53)      | 31.4 (5.54)         | 0.144   |
| ALT (U/L)                | 37.1 (80.0)   | 32.8 (22.4)     | 37.6 (30.5)      | 38.0 (92.6)         | 0.935   |
| Creatinine (µmol/L)      | 76.9 (60.6)   | 74.5 (27.3)     | 92.6 (75.7)      | 75.1 (63.7)         | 0.391   |
| Sodium (mmol/L)          | 139 (4.43)    | 138 (3.94)      | 140 (5.61)       | 139 (4.36)          | 0.576   |
| Prothrombin time (s)     | 16.8 (2.49)   | 16.5 (2.52)     | 17.0 (1.69)      | 16.8 (2.58)         | 0.703   |
| INR                      | 1.39 (0.26)   | 1.36 (0.26)     | 1.41 (0.18)      | 1.39 (0.27)         | 0.679   |
| **TIPS procedure**       |               |                 |                  |                     | 0.520   |
| Stent diameter           |               |                 |                  |                     |         |
| 6 mm                     | 108 (44.4)    | 19 (47.5)       | 12 (48.0)        | 77 (43.3)           |         |
| 7 mm                     | 87 (35.8)     | 16 (40.0)       | 6 (24.0)         | 65 (36.5)           |         |
| 8 mm                     | 48 (19.8)     | 5 (12.5)        | 7 (28.0)         | 36 (20.2)           |         |
| Pre-TIPS PPG*            | 36.8 (7.63)   | 34.8 (5.81)     | 33.7 (10.7)      | 37.5 (7.51)         | 0.080   |
| Post-TIPS PPG*           | 15.9 (5.41)   | 15.3 (4.20)     | 13.1 (7.39)      | 16.3 (5.33)         | 0.088   |
| **Portography**          |               |                 |                  |                     | 0.169   |
| Through SV               | 221 (90.9)    | 37 (92.5)       | 21 (84.0)        | 164 (92.1)          |         |
| Through SMV              | 22 (9.1)      | 3 (7.5)         | 5 (16.0)         | 14 (7.9)            |         |
| **Puncture site**        |               |                 |                  |                     | <0.001  |
| Left branch              | 112 (46.1)    | 7 (17.5)        | 17 (68.0)        | 88 (49.4)           |         |
| Right branch             | 131 (53.9)    | 33 (82.5)       | 8 (32.0)         | 90 (50.6)           |         |
| Embolization             | 166 (68.3)    | 29 (72.5)       | 15 (60.0)        | 122 (68.5)          | 0.569   |

*Data were expressed as means and standard deviation; Other data were presented as frequencies and percentages

AIH autoimmune hepatitis, CTPV cavernous transformation of portal vein, MELD model for end-stage liver disease, PV portal vein, SV splenic vein, SMV superior mesenteric vein, ALT alanine aminotransferase, INR international normalized ratio, PPG portal pressure gradient
Comparison between flow diversion and puncture site

We further evaluated the effect of puncture site on post-TIPS overt HE and compared its predictive ability with flow diversion. In our cohort, the cumulative rate showed no marked difference between puncture of the left and right portal branch (HR 0.69 [95% CI 0.42–1.11]; \( p = 0.12 \)) (Fig. 3B). Similar results were obtained in the multivariable Cox analysis in which puncture site was not significantly correlated with the outcome (data not shown). In the subgroup analyses stratified by puncture site, the increased risk for the SMV superiority type was observed in both subgroups (Additional file 1: Fig. S3A), while in the subgroup analyses stratified by flow diversion, the cumulative rate of post-TIPS overt HE showed no marked difference between puncture of the left and right branch in all three subgroups (Additional file 1: Fig. S3B).

Discussion

In this single-center, retrospective study with relatively large cohort of patients with cirrhosis submitted to TIPS, we found in approximately three quarters of cases the blood from SV and SMV were fully mixed in the intrahepatic portal system under portography, and these cases have comparable risk of postoperative overt HE regardless of the puncture site. For the remaining cases, approximately three quarters of them belong to type A (the right portal branch receives blood from SV and the left branch receives blood from SMV). Besides, portal flow diversion based on intraprocedural portography is an independent predictor of post-TIPS overt HE, in which the SMV superiority type is associated with increased risk of overt HE and ammonia elevation compared with the mixed type.

Hyperammonemia plays a central role in the pathogenesis of overt HE, especially after TIPS creation as this procedure diverts portal blood containing gut-derived neurotoxins into the systemic circulation [15, 16]. Thus, several studies concluded that puncture of the left portal branch might decrease the risk of post-TIPS overt HE based on the hypothesis that the left branch mainly receives blood from SV containing less neurotoxins [7, 11, 12]. However, this hypothesis was based on several animal studies [17, 18], and hemodynamic evidence from human studies (especially from patients with cirrhosis) were scarce. Contrary to previous views, our results showed that in 73.4% of patients with cirrhosis undergoing TIPS the blood from SV and SMV were fully mixed in the portal system, while the percentage of patients with the assumed blood distribution (type B) was only 5.6%. This discrepancy may be attribute to the fact that

\( p = 0.238 \), but the SV superiority type was only associated with a trend of decreased risk at 3 days (adjusted HR 0.52 [95% CI 0.18–1.48]; \( p = 0.223 \)) (Table 3).

Table 2 Summary of outcome measurements during follow-up

|                          | Total N = 243 | SV group N = 40 | SMV group N = 25 | Mixed group N = 178 |
|--------------------------|--------------|----------------|------------------|--------------------|
| Follow-up period (m)*    | 15.8 (9.4–26.5) | 13.5 (5.7–26.2) | 12.9 (4.7–21.4) | 16.9 (5.7–28.3)    |
| Primary outcome: Incidence of post-TIPS overt HE |               |                 |                  |                    |
| Overt HE                 | 67 (27.6)    | 5 (12.5)       | 18 (72.0)        | 44 (24.7)          |
| Grade III or higher      | 59 (24.2)    | 3 (7.5)        | 16 (64.0)        | 40 (22.4)          |
| Recurrent                | 21 (8.6)     | 2 (5.0)        | 8 (32.0)         | 11 (6.2)           |
| Precipitants             |              |                 |                  |                    |
| High-protein intake      | 25 (37.3)    | 2 (40.0)       | 5 (27.8)         | 18 (40.9)          |
| Rebleeding               | 9 (13.4)     | 0 (0.0)        | 2 (11.1)         | 7 (15.9)           |
| Liver failure            | 18 (26.9)    | 2 (40.0)       | 7 (38.9)         | 9 (20.5)           |
| Unclear                  | 15 (22.4)    | 1 (20.0)       | 4 (22.2)         | 10 (22.7)          |
| Secondary outcome 1: Change of ammonia level at 3 days† |               |                 |                  |                    |
| With ammonia elevation   | 81 (66.3)    | 12 (54.5)      | 17 (80.9)        | 52 (65.8)          |
| Elevation* (μmol/L)      | 9 (7–30)     | 4 (10–9)       | 31 (10–36)       | 8 (7–26)           |
| Secondary outcome 2: Change of ammonia level at 1 month§ |               |                 |                  |                    |
| With ammonia elevation   | 57 (76.0)    | 9 (75.0)       | 12 (92.3)        | 36 (72.0)          |
| Elevation* (μmol/L)      | 20 (4–52)    | 18 (1–30)      | 45 (23–60)       | 18 (1–55)          |

* Data were expressed as median (interquartile range); Other data were expressed as frequencies (percentages)
† For the secondary outcome 1, the results were available in 122 patients (22 patients for the SV group, 21 for the SMV group and 79 for the Mixed group)
§ For the secondary outcome 2, the results were available in 75 patients (12 patients for the SV group, 13 for the SMV group and 50 for the Mixed group)
Fig. 3 Post-TIPS overt hepatic encephalopathy in the study population. A Kaplan–Meier curves of patients stratified by flow diversion (SV group, SMV group and mixed group), B Kaplan–Meier curves of patients stratified by puncture site (left branch group and right branch group). SV: splenic vein, SMV: superior mesenteric vein, HR: hazard ratio, CI: confidence interval.
blood distribution depends on multiple factors including venous angles, blood velocity and length of the main PV. Thus, the previous hypothesis might not be applicable to all cirrhotic patients due to individual variation.

Based on these preliminary findings we subsequently combined blood distribution with puncture site to establish a new risk stratification approach based on portal flow diversion, and speculated that this approach is superior than using puncture site in the identification of patients at different risk of post-TIPS overt HE. In our cohort, patients presented with the SMV superiority type was associated with a significantly higher risk of the outcome, and the SV superiority type was related to a 43% decreased risk compared with the mixed type. Moreover, our hypothesis is supported by analyzing the change of serum ammonia level, in which the SMV group showed a substantially higher level within one month compared with the baseline level and the level of other two groups. Of note, we attempt to investigate the predictive value of flow diversion based on the portography after stent insertion, which might be more relevant to the outcome. However, portal flow was mostly diverted through TIPS shunt soon after stent placement and intrahepatic blood distribution was purely visual in some cases. Besides, the diversion degree in post-TIPS portography was affected by multiple factors (e.g. stent size and angle), making the results unreliable and reproducible.

The cumulative rate of post-TIPS overt HE presented no difference between puncture of the left and right portal branch in the entire cohort as well as in subgroups of different flow diversion. This negative result could be explained on several grounds. First, most cases belonged to the mixed type which might not be affected by different puncture site. Second, previous studies suggested that puncture of the left branch has minimal impact on hepatic perfusion and less impairment on liver function since the left branch is smaller with fewer perfusion. However, atrophy of the right lobe and hypertrophy of the caudate and left lobe frequently occur in the presence of advanced cirrhosis [19–21]. Therefore, the effect of puncture site on post-TIPS overt HE is heterogeneous and flow diversion based on portography is a more reliable and accurate approach in the prediction of the outcome.

Our study is of clinical relevance as it reveals another independent risk factor for post-TIPS overt HE. For patients present with SMV superiority type under portography, under-dilated strategy to achieve a higher post-TIPS PPG may be an optimal choice [22, 23], and this subgroup of patients may benefit from pharmacological prophylaxis due to the positive results of the latest RCT [24]. Moreover, the incidence of overt HE in the SMV group was far beyond the reported ranges [4], and these patients were those with type A but were mis-punctured the left portal branch or type B but were mis-punctured the right branch. Since several modalities were developed to visualize the portal system which provides not only anatomical but hemodynamic information [25–27], novel techniques may aid clinicians to visualize blood distribution before procedure and select appropriate portal branch.

Potential limitations exist in the present study. First, patients in the SV group and SMV group were relatively small, limiting the ability to draw firm conclusions. Second, other outcomes such as shunt dysfunction and mortality were not assessed in our study, which were reported to have a correlation with different puncture site [9, 10, 13], though the results were controversial. Third, the reliability of identification of portal flow diversion may be confounded by different catheter position and different contrast dose, and standardized portography protocol should be generated. Forth, potential bias is inherent due to the retrospective nature and single-center design, and prospective studies are warranted to validate these results.

In conclusion, this study showed that in three quarters of patients submitted to TIPS the blood from SV and SMV were fully mixed in the intrahepatic portal system, and for patients with SMV superiority type the risk of post-TIPS overt HE increased significantly.

### Table 3  Association between diversion type and incidence of outcomes

| Diversion type             | HR/OR (95% CI)       | Model A       | Model B       | Model C       |
|----------------------------|----------------------|---------------|---------------|---------------|
| **Outcome 1: Development of overt HE** |                      |               |               |               |
| Mixed                      | Ref                  | Ref           | Ref           |               |
| SV superiority            | 0.57 (0.22–1.45)     | 0.58 (0.24–1.47) | 0.57 (0.22–1.48) |               |
| SMV superiority           | 3.77 (2.09–6.78)     | 3.72 (2.05–6.75) | 3.70 (2.01–6.80) |               |
| **Outcome 2: Ammonia elevation at 3 days** |                      |               |               |               |
| Mixed                      | Ref                  | Ref           | Ref           |               |
| SV superiority            | 0.55 (0.20–1.51)     | 0.58 (0.21–1.59) | 0.52 (0.18–1.48) |               |
| SMV superiority           | 2.94 (0.91–11.75)    | 2.98 (0.93–11.94) | 3.21 (1.07–13.14) |               |
| **Outcome 3: Ammonia elevation at 1 month** |                      |               |               |               |
| Mixed                      | Ref                  | Ref           | Ref           |               |
| SV superiority            | 1.05 (0.28–5.88)     | 1.10 (0.29–6.20) | 1.02 (0.26–5.89) |               |
| SMV superiority           | 3.69 (0.57–73.81)    | 3.76 (0.58–75.43) | 3.82 (0.59–76.94) |               |

*Model A was adjusted for age and Child–Pugh score
*Model B was adjusted for age, Child–Pugh score and post-TIPS portal pressure gradient
*Model C was adjusted for age, Child–Pugh score and post-TIPS portal pressure gradient and puncture site (left/right PV branch)

*For the secondary outcomes, effect of diversion type on the outcomes were evaluated by logistic regression models with odds ratios

Ref reference, HR hazard ratio, OR odds ratio, CI confidence interval, HE hepatic encephalopathy
Portal flow diversion based on portography is more reliable and accurate than puncture site in the stratification of patients at different risk of the outcome, which has the potential to affect decision-making by achieving preprocedural visualization of blood distribution.

**Abbreviations**

HE: Hepatic encephalopathy; TIPS: Transjugular intrahepatic portosystemic shunt; PV: Portal vein; SV: Splenic vein; SMV: Superior mesenteric vein; PPG: Portal pressure gradient; HR: Hazard ratio; OR: Odds ratio; MELD: Model for end-stage liver disease.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12876-022-02447-y.

**Additional file 1.** Fig. S1. Venn diagram showing the distribution of patients with unilateral opacification stratified by blood distribution and flow diversion. SV splenic vein; SMV superior mesenteric vein. Fig. S2. Cumulative incidence of post-TIPS overt hepatic encephalopathy for patients with different flow diversion based on Fine-Gray competing risk models. P values were calculated by Fine-Gray tests. CI confidence interval; sHR subdistribution hazard ratio. **Fig. 4** Change of ammonia level before and after TIPS creation. A and C Ammonia level before and at 3 days after procedure from 122 patients. B and D Ammonia level before and at 1 month after procedure from 75 patients. A, B In scatterplots, points below the diagonal line represent cases with the 3 days/1 month ammonia lever lower than the baseline level, and points above the diagonal line represent cases with the 3 days/1 month ammonia level higher than the baseline level. C, D Boxplots show the median (interquartile range) of ammonia level. P value were calculated using Mann–Whitney U tests.

**Acknowledgements**

We want to express our gratitude to Chuang Sun for statistical analysis.

**Author contributions**

BX: Conceptualization. CY: Writing-original draft, Methodology. YC: Data-collection, Methodology. CW: Data-analysis and interpretation. JL: Data-collection, Methodology. SH: Writing-review and editing. CZ: Data-collection, Software. YW: Software. SJ: Data-analysis and interpretation. TL: Data-collection. YB: Software. WY: Data-collection, Software. All authors read and approved the final manuscript.

**Funding**

This study was funded by National Natural Science Foundation of China (81873917).
Availability of data and materials
The dataset used and analyzed in the present study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was approved by the institutional review board of Tongji Medical College. Informed consent was waived by the IRB of Tongji Medical College due to the retrospective nature of the study, and all patients data have been anonymized.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue #1277, Wuhan 430022, China. 2 Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China.

Received: 5 May 2022 Accepted: 19 July 2022
Published online: 29 July 2022

References

1. de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52. https://doi.org/10.1016/j.jhep.2015.05.022.
2. European Association for The Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–60. https://doi.org/10.1016/j.jhep.2018.03.024.
3. Riggio O, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103:2738–46. https://doi.org/10.1111/j.1572-0241.2008.02102.x.
4. Vilstrup H, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (Baltimore, MD). 2014;60:715–35. https://doi.org/10.1002/hp.27210.
5. Casado M, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology. 1998;114:1296–303.
6. Rossé M. TIPS. 25 years later. J Hepatol. 2013;59:1081–93. https://doi.org/10.1016/j.jhep.2013.06.014.
7. Chen L, et al. Outcomes of transjugular intrahepatic portosystemic shunt through the left branch vs. the right branch of the portal vein in advanced cirrhosis: a randomized trial. Liver Int. 2009;29:1101–9. https://doi.org/10.1111/j.1478-3231.2009.02016.x.
8. Xue H, et al. Follow-up study of transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension. Dig Dis Sci. 2011;56:3350–5. https://doi.org/10.1007/s00330-011-1744-5.
9. Bai M, et al. Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt. World J Gastroenterol. 2014;20:774–85. https://doi.org/10.3748/wjg.v20.i3.774.
10. Chen S-L, Hu P, Lin Z-P, Zhao J-B. The effect of puncture sites of portal vein in TIPS with ePTFE-covered stents on postoperative long-term clinical efficacy. Gastroenterol Res Pract. 2019;2019:2935498. https://doi.org/10.1155/2019/2935498.
11. Luo S-H, Chu J-G, Huang H, Zhao G-R, Yao K-C. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy. World J Gastroenterol. 2019;25:1088–99. https://doi.org/10.3748/wjg.v25.i10.1088.
12. Zhou Y, et al. Efficacy of puncturing different portal vein branch during transjugular intrahepatic portosystemic shunt with 8 mm covered stent: a propensity-score analysis. Eur J Gastroenterol Hepatol. 2021. https://doi.org/10.1097/MEG.0000000000002133.
13. Zuo K, Wang C, Wang J, Xia F-F, Song T. Transjugular intrahepatic portosystemic shunt through left branch versus right branch of portal vein: a meta-analysis. Abdom Radiol (NY). 2021;46:1718–25. https://doi.org/10.1007/s00261-020-02789-9.
14. Yang C, et al. Effect of splenectomy on the outcomes in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunt. J Gastroenterol Hepatol. 2021. https://doi.org/10.1111/jgh.15543.
15. Olde Damink SW, et al. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPS. Hepatology. 2002;36:1163–71. https://doi.org/10.1053/jhep.2002.36497.
16. Riggio O, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis. 2012;16:133–46. https://doi.org/10.1016/j.clld.2011.12.008.
17. Ursic M, et al. Gross anatomy of the portal vein and hepatic artery ramifications in dogs: corrosion cast study. Anat Histol Embryol. 2007;36:83–7.
18. Mogicato G, Vautravers G, Meynaud-Collard P, Deviers A, Sautet J. Blood flows in tributaries of the portal vein: anatomical and angiographic studies in normal beagle dogs. Anat Histol Embryol. 2015;44:460–7. https://doi.org/10.1111/aje.12161.
19. Brown JJ, Naylor MJ, Vagan N. Imaging of hepatic cirrhosis. Radiology. 1997;202:1–16.
20. Aways H, et al. Cirrhosis: modified caudate-right lobe ratio. Radiology. 2002;224:769–74.
21. Hussain SM, Reinhold C, Mitchell DG. Cirrhosis and lesion characterization at MR imaging. Radiographics. 2009;29:1637–52. https://doi.org/10.1148/rg.296095308.
22. Wang Q, et al. Eight millimeter covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. J Hepatol. 2017;67:508–16. https://doi.org/10.1016/j.jhep.2017.05.006.
23. Scheips F, et al. Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis. Clin Gastroenterol Hepatol. 2018. https://doi.org/10.1016/j.cgh.2018.01.029.
24. Bureau C, et al. The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial. Ann Intern Med. 2021;174:633–40. https://doi.org/10.17326/m20-0202.
25. Burke CT, Weeks SM, Mauro MA, Jaques PF. CO2 splenoportography for evaluating the splenic and portal veins before or after liver transplantation. J Vasc Interv Radiol. 2004;15:1161–5.
26. Maruyama H, et al. Carbon dioxide-based portography: an alternative to conventional imaging with the use of iodinated contrast medium. J Gastroenterol Hepatol. 2010;25:1111–6. https://doi.org/10.1111/j.1440-1746.2010.06248.x.
27. Luo X, et al. Transjugular intrahepatic portosystemic shunt creation: three-dimensional roadmap versus CO2 wedged hepatic venography. Eur Radiol. 2018;28:3215–20. https://doi.org/10.1007/s00380-018-5316-3.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.